Sermonix Pharmaceuticals and Regor Therapeutics have announced a strategic partnership to discover and develop therapeutics in the breast oncology area.
The partnership aims for the optimisation of the Regor Computer Accelerated Rational Discovery (rCARD) platform to identify new targets and treatments that meet individuals’ clinical requirements and preferences.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It brings together the strengths of both companies, combining expertise from early discovery to commercial launch.
This synergy is expected to yield treatments that not only demonstrate efficacy but also offer improved quality of life and tolerability.
Regor’s rCARD platform is designed to accelerate the discovery and development of therapies from target detection and validation to translational research and clinical development.
Sermonix Pharmaceuticals CEO and founder Dr David Portman stated: “At Sermonix, we believe patients deserve not only highly efficacious treatments but also ones that are well-tolerated and potentially improve quality of life for breast cancer patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Deep patient insights and the potential to develop targets that can ultimately provide efficacy while addressing areas of key concerns to patients such as vaginal, bone and cardiovascular health would be fulfilling on the promise of optimised drug development.”
Sermonix’s Phase III asset, oral lasofoxifene, is currently in development for oestrogen receptor 1-mutated ER+ human epidermal growth factor receptor 2 (HER2)- metastatic breast cancers.
The company is enrolling subjects to assess lasofoxifene in the ELAINE-3 trial, which compares the oral therapy in conjunction with the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor abemaciclib against fulvestrant + abemaciclib in pre-and post-menopausal patients with locally advanced or metastatic ER+/HER2- breast cancer with mutations of oestrogen receptor 1.
